Table 2.
Trials comparing CHOP versus R-CHOP.
| Reference | Population | Treatment arms | PFS | OS |
|---|---|---|---|---|
| Groupe d’Etude des Lymphomes de l’Adulte, 2002 | DLBCL, 60–80 years | +R-CHOP versus | 54% to 5 years | 58% to 5 years |
| ++CHOP | 30% to 5 years | 45% to 5 years | ||
| RICOVER-60 | 1222 patients, 60–80 years | CHOP-14 × 6 | 47.2% | 67.7% (3 years) |
| CHOP-14 × 8 | 53.2% | 66% | ||
| R-CHOP14 × 6 | 66.5% | 78.1% | ||
| R-CHOP14 × 8 | 63% | 72.5% | ||
| Mab-Thera International Trial, 2006 | 18–60 years, low and low-intermediate risk (IPI) | R-CHOP-like | 74.3% to 6 years | 90.1% (6 years) |
| +++CHOP like | 55.8% to 6 years | 80.1% (6 years) |
+
R = rituximab (375 mg/m2). ++CHOP = cyclophosphamide, 750 mg/m2; doxorubicin, 50 mg/m2; vincristine, 1.4 mg/m2, with capping at 2 mg; and oral prednisone, 100 mg daily on days 1–5. +++CHOP like = CHOP ± etoposide.
DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; OS, overall survival; PFS, progression-free survival.